Vaxelis® (DTaP5-HB-IPV-Hib vaccine) as primary and booster vaccination in infants and toddlers: a profile of its use
| Autor: | Katherine A. Lyseng-Williamson, Gillian M. Keating, Yahiya Y. Syed |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
business.industry
Tetanus Poliovirus Neisseria meningitidis fungi Toxoid medicine.disease_cause medicine.disease complex mixtures Virology 03 medical and health sciences 0302 clinical medicine Immunization Hib vaccine Tolerability Antigen 030225 pediatrics Immunology Medicine Pharmacology (medical) 030212 general & internal medicine business |
| Zdroj: | Drugs & Therapy Perspectives. 33:208-213 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-017-0400-3 |
| Popis: | Vaxelis® (DTaP5-HB-IPV-Hib vaccine) is a fully liquid, ready-to-use, hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, five acellular pertussis antigens, hepatitis B surface antigen, inactivated poliovirus and the Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to the outer membrane protein complex of Neisseria meningitidis. In pivotal clinical studies in infants and toddlers, Vaxelis® was highly immunogenic for all its component toxoids/antigens when administered by three different schedules. In general, primary endpoints of seroprotection or vaccine response rates with Vaxelis® met the predefined acceptability criteria and were noninferior to those with comparator vaccines (Infanrix® hexa or Pentacel® + Recombivax HB®). Vaxelis® can be coadministered with a number of common childhood vaccines. In clinical studies, Vaxelis® was generally well tolerated with a tolerability profile similar to that of the comparator vaccines. Available clinical data indicate that Vaxelis® is a new hexavalent vaccine option for immunization against several serious childhood infectious diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink